Published in Clin Cancer Res on May 18, 2010
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron (2011) 2.69
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
Crossing the endothelial barrier during metastasis. Nat Rev Cancer (2013) 2.00
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med (2015) 1.83
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget (2013) 1.64
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene (2012) 1.48
The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ (2011) 1.44
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther (2013) 1.44
Mesenchymal stromal cell secretome up-regulates 47 kDa CXCR4 expression, and induce invasiveness in neuroblastoma cell lines. PLoS One (2015) 1.42
Cell, isoform, and environment factors shape gradients and modulate chemotaxis. PLoS One (2015) 1.42
Glutathione S-transferase P influences redox and migration pathways in bone marrow. PLoS One (2014) 1.38
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37
Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res (2011) 1.33
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A (2010) 1.30
The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions. J Biol Chem (2011) 1.23
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A (2013) 1.17
miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. Mol Cancer (2013) 1.15
Fucoidan as a marine anticancer agent in preclinical development. Mar Drugs (2014) 1.14
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics (2015) 1.11
Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer (2014) 1.11
Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med (2011) 1.11
Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem (2012) 1.10
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.08
Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer (2011) 1.08
Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflammation (2011) 1.08
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica (2013) 1.05
Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment (2014) 1.05
Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem (2012) 1.05
Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives. Front Immunol (2015) 1.05
Miro-1 links mitochondria and microtubule Dynein motors to control lymphocyte migration and polarity. Mol Cell Biol (2014) 1.04
The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol (2014) 1.03
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2012) 1.01
Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling. Neoplasia (2011) 1.01
The role of high mobility group box 1 in innate immunity. Yonsei Med J (2014) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One (2014) 0.99
Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide. Bioconjug Chem (2011) 0.99
Stromal cell-derived factor-1β mediates cell survival through enhancing autophagy in bone marrow-derived mesenchymal stem cells. PLoS One (2013) 0.98
Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem (2011) 0.98
Macrophages and chemokines as mediators of angiogenesis. Front Physiol (2013) 0.98
Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells. Oncotarget (2015) 0.97
Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep (2014) 0.97
CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133- cells. Lab Invest (2011) 0.97
Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma xenografts. Oncotarget (2013) 0.96
Structural determinants of ubiquitin-CXC chemokine receptor 4 interaction. J Biol Chem (2011) 0.96
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci (2014) 0.96
CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J Neuroinflammation (2014) 0.96
SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer (2011) 0.95
Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm (2014) 0.94
Heteromerization of chemokine (C-X-C motif) receptor 4 with α1A/B-adrenergic receptors controls α1-adrenergic receptor function. Proc Natl Acad Sci U S A (2015) 0.94
Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol (2012) 0.94
Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne) (2015) 0.94
CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem (2013) 0.93
Cutaneous inflammatory malignant fibrous histiocytoma presenting with a leukemoid reaction: a case report and review of the literature. Case Rep Med (2012) 0.93
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. Mol Ther (2011) 0.93
IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One (2015) 0.92
Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One (2013) 0.92
Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One (2013) 0.92
AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. Am J Cancer Res (2011) 0.91
Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer (2014) 0.91
NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis. J Pathol (2014) 0.91
Bone metastasis and the metastatic niche. J Mol Med (Berl) (2015) 0.90
C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res (2014) 0.90
CXC chemokine ligand 12/stromal cell-derived factor-1 regulates cell adhesion in human colon cancer cells by induction of intercellular adhesion molecule-1. J Biomed Sci (2012) 0.90
Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron (2014) 0.90
Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS One (2013) 0.90
Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm (2011) 0.90
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer(1,2.) Transl Oncol (2014) 0.89
The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol (2013) 0.89
Quantitative phosphoproteomics of CXCL12 (SDF-1) signaling. PLoS One (2011) 0.88
Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol Cancer Ther (2013) 0.88
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer Prev Res (Phila) (2012) 0.88
The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene (2015) 0.87
The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol (2014) 0.87
Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm (2014) 0.87
Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget (2015) 0.87
BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer (2014) 0.87
Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer (2013) 0.87
CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain. Int J Mol Sci (2013) 0.87
Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk. Cell Commun Signal (2012) 0.87
Improvement of CXCR4 tracer specificity for PET imaging. J Control Release (2011) 0.87
Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis (2013) 0.87
Expressions of CXCR7/ligands may be involved in oral carcinogenesis. J Mol Histol (2011) 0.87
Genetics of breast cancer bone metastasis: a sequential multistep pattern. Clin Exp Metastasis (2014) 0.87
Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity. Oncotarget (2015) 0.87
Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. Pulm Circ (2011) 0.87
Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma. Cancers (Basel) (2011) 0.86
Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue. J Mol Histol (2013) 0.86
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biol Ther (2012) 0.86
Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res (2007) 1.51
Protein kinase C as a therapeutic target. Clin Cancer Res (2006) 1.31
Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol (2008) 1.13
Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res (2008) 1.11
AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol (2006) 0.90
HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay. Virology (2011) 0.90
A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery. Methods Mol Biol (2009) 0.87
A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection. J Cardiovasc Pharmacol (2002) 0.86
The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol (2011) 0.85
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol (2009) 0.85
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach. J Am Chem Soc (2011) 0.80
The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol (2005) 0.79
Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity. J Inorg Biochem (2011) 0.79
Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition. J Med Chem (2006) 0.77
Antitumor actions of ruthenium(III)-based nitric oxide scavengers and nitric oxide synthase inhibitors. Mol Cancer Ther (2011) 0.77
Ruthenium as an effective nitric oxide scavenger. Curr Top Med Chem (2004) 0.75
Ruthenium(III) polyaminocarboxylate complexes: efficient and effective nitric oxide scavengers. Inorg Chem (2003) 0.75
Ruthenium(III) triazacyclononane dithiocarbamate, pyridinecarboxylate, or aminocarboxylate complexes as scavengers of nitric oxide. Inorg Chem (2003) 0.75
The ruthenium-based nitric oxide scavenger, AMD6221, augments cardiovascular responsiveness to noradrenaline in rats with streptozotocin-induced diabetes. Eur J Pharmacol (2005) 0.75